Literature DB >> 24254895

Hereditary and Acquired Thrombophilia in Splanchnic Vein Thrombosis: A Single-Center Experience.

Deepti Mutreja1, Mrinalini Kotru1, Sudha Sazawal1, Ravi Ranjan1, Amit Sharma1, Subrat Kumar Acharya2, Renu Saxena3.   

Abstract

The purpose of this study was to characterize differences in the prevalence of hereditary and acquired thrombophilia in patients with splanchnic vein thrombosis (SVT). A total of 88 consecutive patients with SVT, including Budd Chiari Syndrome (n = 47) and portal extrahepatic portal vein obstruction (n = 41), underwent comprehensive thrombophilia testing, including testing for heritable and acquired causes. In 33 (37.5%) patients, etiology could be explained by at least 1 of the heritable etiologic factors, and 31 (35.2%) patients could be explained by at least 1 of the acquired causes studied. The combination of multiple concurrent factors was present in 9 (11.4%) patients. Among the heritable causes, the risk of SVT was found increased in the presence of thrombophilia resulting from the deficiencies of the naturally occurring anticoagulant proteins, and the acquired thrombogenic factors were significantly associated with causation of thrombosis in adult patients with SVT.
© The Author(s) 2013.

Entities:  

Keywords:  clinical thrombophilia; deep venous thrombosis; hypercoagulability; molecular diagnostics; thrombophilia; thrombosis

Mesh:

Year:  2013        PMID: 24254895     DOI: 10.1177/1076029613511520

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  2 in total

Review 1.  Prothrombin gene mutation in Budd-Chiari syndrome-The first case report from India.

Authors:  Abhinav Jain; Akash Shukla
Journal:  Indian J Gastroenterol       Date:  2018-04-04

2.  Clinical presentations, risk factors, treatment and outcomes in patients with splanchnic vein thrombosis: a single-center experience.

Authors:  Kelsey Klute; Ersilia M DeFilippis; Kelissa Shillingford; John Chapin; Maria T DeSancho
Journal:  J Thromb Thrombolysis       Date:  2016-08       Impact factor: 2.300

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.